Drug Profile
Research programme: respiratory disease therapeutics - Boehringer Ingelheim
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Germany
- 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
- 17 Apr 2013 Preclinical trials in Respiratory tract disorders in Germany (unspecified route)